Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292141 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29511122 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL20732314 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL16412291 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL30097312 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL20732317 | 0.97 | TLR2 (0.43) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29511192 | 0.97 | TLR2 (0.43) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29423583 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 | |
| SCHEMBL12658043 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 | |
| SCHEMBL30412459 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-11510988-B2 | Targeting aminoacid lipids | MERCK PATENT GMBH (DE) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | MDM4 1569/4885TP53 1229/4885MDM2 3842/4885 |
| US-11510988-B2 | Targeting aminoacid lipids | PTDSS2, DNPEP, FABP1 | MDM4 3004/4885TP53 836/4885MDM2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.